First in the Nation, FDA-Approved Phase II Mesenchymal Stem Cell Therapy for Parkinson’s Disease Begins

A Phase II clinical trial to assess mesenchymal adult stem cells as a disease-modifying therapy for Parkinson’s disease has been launched at The University of Texas Health Science Center at Houston